Study objectives: To examine the association of empiric inpatient antibiotic treatment of community-acquired pneumonia (CAP) with mortality, and whether this association varies from year to year. Design: Population-based, retrospective study adjusting for demographics, comorbidities, and clinical characteristics. Setting: Acute-care hospitals in 10 western states. Patients: A group of 10,069 Medicare beneficiaries aged ≥ 65 years who were hospitalized with CAP during fiscal years 1993, 1995, and 1997. Measurements and results: We examined the risk for mortality during the 30 days after admission to the hospital. The impact of specific antibiotic regimens varied greatly from year to year. In 1993, therapy with a macrolide plus a β-lactam was associated with significantly lower mortality than therapy with either a β-lactam alone (adjusted odds ratio [AOR], 0.42; 95% confidence interval [CI], 0.25 to 0.69) or other regimens that did not include a macrolide, β-lactam, or fluoroquinolone (AOR, 0.35; 95% CI, 0.20 to 0.62). Those associations were not observed in 1995 or 1997. Lower mortality was associated with fluoroquinolone monotherapy compared with β-lactam monotherapy in 1997 (AOR, 0.27; 95% CI, 0.07 to 0.96) and with macrolide monotherapy compared with other regimens in 1995 (AOR, 0.24; 95% CI, 0.06 to 0.93), but the number of patients who received these regimens was small. Conclusions: The inclusion of a macrolide or a fluoroquinolone in initial empiric CAP treatment was associated with improved survival, but this association varied from year to year, perhaps as a result of a temporal variation in the incidence of atypical pathogen pneumonia. Improved testing and surveillance for atypical pathogen pneumonia are needed to guide empiric therapy.
|Original language||English (US)|
|Number of pages||7|
|State||Published - May 2001|
Bibliographical noteFunding Information:
The opinions expressed are those of the authors and do not necessarily reflect the policy of the US Department of Health and Human Services and the Health Care Financing Administration. The authors have no financial involvement in and received no support from any organization with a direct commercial financial interest in the subject of this manuscript. This work was funded entirely by the Health Care Financing Administration.
- Atypical pathogen